PF-07921585

N/A

Report date: 2025/08/20 20:01:27

Base Information

Drug NamePF-07921585
Drug Alias NamePF-07921585
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionInterleukin-12 subunit beta stimulants
TargetsInterleukin-12 subunit beta
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A